NCT03755778 - Drug-Drug Interaction Study Between EDP-938, Itraconazole, Rifampin, and Quinidine in Healthy Subjects | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 29, 2018

Primary Completion Date

January 21, 2019

Study Completion Date

January 27, 2019

Conditions

RSV Infection

Interventions

DRUG

EDP-938

Subjects will receive EDP-938 once daily on Day 1 and 14 (Part 1)

DRUG

EDP-938

Subjects will receive EDP-938 once daily on Day 1 and 14 (Part 2)

DRUG

EDP-938

Subjects will receive EDP-938 once daily on Day 1 and 8 (Part 3)

DRUG

Itraconazole

Subjects will receive itraconazole once daily from Day 5 to Day 18

DRUG

Rifampin

Subjects will receive rifampin once daily from Day 5 to Day 16

DRUG

Quinidine

Subjects will receive quinidine once daily from Day 5 to Day 12

Trial Locations (1)

Pharmaceutical Research Associates, Inc.,, Lenexa